677 Lower risk of cardiovascular (CV) events and death in men receiving ADT by gonadotropin releasing hormone (GnRH) antagonist, degarelix, compared with luteinising hormone-releasing (LHRH) agonists

Autor:	Peter C. Albertsen, Bertrand Tombal, Tine Kold Olesen, A. De La Taille, B.E. Persson, Jan Nilsson, E. Van Der Meulen
Rok vydání:	2013
Předmět:	medicine.medical_specialty business.industry Urology GnRH Antagonist Gonadotropin-releasing hormone Lower risk Luteinising hormone chemistry.chemical_compound Endocrinology chemistry Internal medicine medicine Degarelix business
Zdroj:	European Urology Supplements. 12:e677-e678
ISSN:	1569-9056
DOI:	10.1016/s1569-9056(13)61159-8
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_________::18834ddd565a9e1feb75ced4960f6d42 https://doi.org/10.1016/s1569-9056(13)61159-8 Zobrazit plný text záznamu Full Text from ScienceDirect